Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Active, not recruiting · NCT06678074 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT06678074 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Implicit Bioscience | 3 |
| University of Virginia | 201 |
| Washington University School of Medicine | 475 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Virginia | Charlottesville | United States | 1 |
| Washington University School of Medicine | St Louis | United States | 895 |